Kidney Week 2024 Live Event: October 25th - Day #2 - 10/25/2024
Obesity Management and Kidney Health: Live Expert Panel - Live Event. 09/16/2024.
Kidney Week 2024 Live Event: October 24th - Day #1 - 10/24/2024
Dr. Roy-Chaudhury will head up an organization鈥攚ith nearly 21,000 health professionals representing 140 countries鈥攄edicated to leading the fight against kidney diseases.
IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition鈥檚 pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23鈥� 27.
Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients鈥� kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23鈥� 27.
For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)鈥攁 procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23鈥�27.
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23鈥�27.
IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients鈥� kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab鈥檚 potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23鈥� 27.
Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA鈥揳ssociated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA鈥揳ssociated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23鈥� 27.
Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically evaluated proteins individually, which limits their prognostic power. The National Institute of Diabetes and Digestive and Kidney Diseases鈥� (NIDDK鈥檚) CKD Biomarkers Consortium of investigators recently developed and tested novel dimensions of kidney health by combining a set of 17 urine and plasma biomarkers that had been individually associated with CKD progression. The research will be presented at ASN Kidney Week 2024 October 23鈥� 27.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients鈥� age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 鈥� 27.
A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades. Also, type 2 diabetes and hypertension were the leading causes of CKD-related deaths in women. The research will be presented at ASN Kidney Week 2024 October 23鈥� 27.
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23鈥�27.
Investigators recently uncovered key insights into newly defined rejection entities in kidney transplantation that may offer improved patient risk categorization post-transplant. The research will be presented at ASN Kidney Week 2024 October 23鈥� 27.
Chronic kidney disease is a progressive condition that affects more than 10% of the general population worldwide, amounting to 800 million individuals.1 Glomerular diseases (GD), excluding diabetic nephropathy, account for approximately 25% of the cases of kidney diseases worldwide.2 Given the magnitude of long-term morbidity from GD鈥� particularly the frequent manifestation in younger patients鈥攄iagnosing it efficiently and optimizing management to control diseases and prevent progressive kidney diseases is paramount.
Largest Global Gathering of Kidney Professionals Expands Program to Include More Breaking Research and Focused Discussions on Key Public Health and Policy Issues
ASN Kidney Translation Series podcast episode, led by Matt Sparks, related to the ASN New Initiative Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
